|Bid||41.61 x N/A|
|Ask||41.62 x N/A|
|Day's Range||41.24 - 41.86|
|52 Week Range||31.03 - 46.51|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||13.62|
|Earnings Date||Jul 30, 2021|
|Forward Dividend & Yield||0.88 (2.11%)|
|Ex-Dividend Date||May 25, 2021|
|1y Target Est||N/A|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
German healthcare group Fresenius has picked former Siemens manager Michael Sen to lead its Kabi generic infusion drugs division, it said on Tuesday. Sen succeeds Mats Henriksson, who is leaving the company over differences of opinion on strategy for the division that has been a major profit driver for the group over recent years. Sen was a Siemens board member from 2017 to 2020 and was responsible for its Healthineers and Siemens Energy businesses.
The Covid-19 situation has improved in the continent with cases falling and vaccine rollouts continuing.